Antigua and Barbuda vs Fiji: Prevalence of hepatitis B surface antigen (HBsAg), 2026 methodology
Antigua and Barbuda
0.2%
in 2024
Fiji
0.2%
in 2024
Antigua and Barbuda rank
98th
Fiji rank
98th
Prevalence of hepatitis B surface antigen (HBsAg), 2026 methodology over time
- Antigua and Barbuda
- Fiji
How they compare
Antigua and Barbuda currently reports 0.2% against 0.2% in Fiji, a difference of 0.0%.
The two have swapped places 3 times across 10 shared years of data; in 2015 it was Antigua and Barbuda ahead.
Antigua and Barbuda ranks 98th and Fiji ranks 98th of 246 countries.
Across the 2 decades both report, Antigua and Barbuda averaged higher in 1 and Fiji in 1.
Head to head by decade
| Decade | Antigua and Barbuda | Fiji | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 0.3% | 0.3% | 0.0% | Antigua and Barbuda |
| 2020s | 0.2% | 0.3% | 0.1% | Fiji |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher prevalence of hepatitis b surface antigen (hbsag), 2026 methodology, Antigua and Barbuda or Fiji?
- Antigua and Barbuda, at 0.2% against 0.2% in Fiji as of 2024.
- What is the difference in prevalence of hepatitis b surface antigen (hbsag), 2026 methodology between Antigua and Barbuda and Fiji?
- 0.0%, with Antigua and Barbuda ahead.
- How many years of comparable data are there for Antigua and Barbuda and Fiji?
- 10 years are reported by both, from 2015 to 2024.
- How do Antigua and Barbuda and Fiji rank globally for prevalence of hepatitis b surface antigen (hbsag), 2026 methodology?
- Antigua and Barbuda ranks 98th and Fiji ranks 98th of 246 countries.
- Where does this data come from?
- United Nations Statistics Division, SDG Global Database, published as Prevalence of hepatitis B surface antigen (HBsAg), 2026 methodology (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.